Comparison of M-2 protocol with COP in patients with nodular lymphoma.
58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens-(cyclophosphamide, vincristine and prednisone (COP), and BCNU , cyclophosphamide, vincristine, melphalan and prednisone (M-2) - to compare remission induction and duration as well as survival. The two groups were comparable for age, stage IV and histology. The complete response for each combination was greater than 80%. Median duration of remission for the COP-treated patients is 18 months. Remission duration and survival are superior for M-2-treated patients. The difference in remission duration and survival advantage is statistically significant for the M-2 protocol compared with COP at 5 years (p less than 0.01).
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001772:Blood Cell Count; D002330:Carmustine / Q000008:administration & dosage / Q000633:toxicity; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008558:Melphalan / Q000008:administration & dosage / Q000633:toxicity; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000633:toxicity; D011336:Probability; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage / Q000633:toxicity
D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone